Viridian Therapeutics (VRDN) Report Interpretation

Overview

Goldman Sachs summarizes a discussion with TED specialist Dr. Shoaib Ugradar on Viridian's recent Lumvoa launch, elegrobart's prospective role, and the emerging TSHR class. The specialist expects Lumvoa to become the dominant active-TED treatment as familiarity and access improve, while elegrobart could broaden treatment uptake in chronic disease.

Core views

The specialist expects Tepezza to remain the preferred near-term option for the next 6–8 months because clinicians already know the product. However, Lumvoa's five-infusion course versus Tepezza's eight is already influencing patient choice: around 30% of patients offered both in the expert's clinic selected Lumvoa. He described the two products as having comparable efficacy and safety, while noting that he needs more real-world Lumvoa experience before being fully confident in its results. As familiarity builds and Lumvoa receives a permanent J-code, he projects Lumvoa usage could reach 60–70% after nine months and 80% of the U.S. market by the end of next year. The report argues that chronic TED is an important expansion opportunity. The specialist said Tepezza has struggled in this population because patients are often discharged after two years, clinicians may equate chronic disease with inactive disease, and many patients are managed outside specialist settings. In his own practice, he uses Tepezza in 85–90% of qualifying chronic patients based on proptosis severity. He expects Lumvoa and Tepezza ultimately to show similar efficacy in chronic TED, but believes Lumvoa's chronic-TED label data could make access easier. He also expects the two companies' marketing efforts to increase disease awareness and expand a chronic market that can grow because TED is lifelong and new patients continue to be diagnosed. Reimbursement has not been a hurdle in the specialist's clinic despite Lumvoa lacking a permanent J-code; its billing system has a 98% approval rate. Prior-authorization timing was described as roughly 15 days for Medicare and about one month for commercial insurance, comparable with Tepezza. The report nevertheless notes that other centers may be less successful, and that infusion centers could favor Tepezza because five Lumvoa infusions may generate less infusion-service revenue than eight Tepezza infusions. The specialist also viewed Viridian's smaller, focused commercial organization as potentially better positioned to build medical-community relationships than what he regarded as unfocused Tepezza marketing. For longer-term competition, the specialist sees little role for Tepezza's on-body injector. He considers it less convenient than a quick subcutaneous autoinjector and less effective than IV therapies, citing device-placement, infection, and incomplete-delivery concerns. He believes elegrobart could be a differentiated, easy-to-use subcutaneous option and could attract at least an additional 40% of untreated chronic-TED patients, although he does not expect it to displace Lumvoa or Tepezza in efficacy. Since 25–40% of Tepezza-treated patients require retreatment within a year, he sees an initial IV course followed by subcutaneous maintenance as a practical way to sustain disease control. Assuming all four products are commercialized, the expert forecasts that in five years Lumvoa will hold 80% of moderate-to-severe active TED, elegrobart 5–10%, and Tepezza IV 10%. In chronic TED, he forecasts a 40%/40%/20% split for elegrobart, Lumvoa, and Tepezza IV, respectively. He is also highly enthusiastic about TSHR-targeting therapies because they directly address a key TED driver, unlike the more indirect IGF-1R approach. He believes the class could offer greater efficacy, safety, speed, convenience, shorter treatment duration, and more durable responses, though an approved therapy remains several years away. Viridian's upcoming milestones include a planned 1Q27 BLA submission for VRDN-003, 2H26 Phase 1 IgG proof-of-concept data for VRDN-008, a planned 4Q26 IND submission for its TSHR program, and 2026 development-plan communication for VRDN-006. Goldman Sachs values VRDN at $40 over 12 months using a DCF without M&A consideration, a 15% WACC, and 0% terminal growth. The WACC is within its 15–19% pre-commercial-company range, while the zero terminal-growth assumption reflects TED patents and potential extensions ending shortly after 2040.

Analysis framework

The report uses specialist interview evidence to assess prescribing behavior, treatment convenience, reimbursement, chronic-TED access, competitive positioning, and potential market-share outcomes. It then applies a DCF valuation using stated discount-rate and terminal-growth assumptions.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  Discounted cash flow valuation

  Goldman Sachs derives its $40 12-month target using a DCF without M&A consideration, discounting expected cash flows with a 15% WACC and applying 0% terminal growth.

• Industry AnalysisSupply-demand framework

  TED treatment-market share and access analysis

  The report uses the specialist's views on patient preference, prescriber familiarity, reimbursement, treatment convenience, chronic-disease access, and competition to form market-share expectations for Lumvoa, elegrobart, and Tepezza.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Viridian Therapeutics (VRDN)

  Primary covered company; its Lumvoa launch, elegrobart opportunity, and TSHR pipeline are the report's focus.

  Strengths

  Lumvoa's shorter five-infusion course, potential chronic-TED label benefit, focused commercial strategy, and TSHR pipeline optionality.

  Weaknesses

  Lumvoa remains early in launch, and real-world performance is still being established by the specialist.

  Comparison

  The specialist expects Lumvoa to gain share from Tepezza as clinician familiarity grows; elegrobart is viewed as more convenient than Tepezza OBI but not as an efficacy-led replacement for IV therapies.

  Risks

  Regulatory or commercialization failure for veli or ele, lower TED market potential, and competition from new subcutaneous and other innovative TED approaches.

• Amgen / Tepezza

  Competitor therapy in the TED market.

  Strengths

  Prescriber familiarity supports its preferred status over the next 6–8 months; IV therapy is viewed as more effective than Tepezza OBI.

  Weaknesses

  Eight infusions, chronic-TED education and access barriers, and marketing viewed by the specialist as poorly coordinated.

  Comparison

  Lumvoa's five infusions may improve patient preference; elegrobart's autoinjector is viewed as more convenient than Tepezza OBI.

  Risks

  The specialist forecasts declining relative share as Lumvoa and elegrobart become established.

Key data

• 12-month target price$40.00DCF-based target without M&A consideration
• Current price$24.80Price as of 19 Aug 2026 close
• Implied upside61.3%From the stated price and target price
• Lumvoa expected U.S. market share60–70% after 9 months; 80% by the end of next yearSpecialist projection as prescriber experience and a permanent J-code develop
• Five-year active-TED share forecastLumvoa 80%; elegrobart 5–10%; Tepezza IV 10%Assumes all four products are commercially available
• Five-year chronic-TED share forecastelegrobart 40%; Lumvoa 40%; Tepezza IV 20%Specialist projection
• Retreatment rate25%–40%Share of Tepezza-treated patients the specialist said require retreatment within a year
• DCF assumptions15% WACC; 0% terminal growth rateWACC is within Goldman Sachs' 15–19% range for pre-commercial companies

Impact & implications

The report's central implication is that Lumvoa's shorter course and potential chronic-TED label advantage could support substantial uptake, while elegrobart may broaden treatment use in chronic disease and maintenance settings. Viridian's TSHR program represents a longer-dated opportunity, but approved TSHR therapies are still several years away.

Risks

• Veli and ele may fail to obtain regulatory approval or commercialize.
• The TED market opportunity may be lower than anticipated.
• Competition could intensify, including from new subcutaneous programs and other innovative TED approaches.

What to watch

• Lumvoa adoption as prescribers gain real-world experience and as a permanent J-code becomes available.
• VRDN-003's planned BLA submission in 1Q27.
• VRDN-008 Phase 1 IgG proof-of-concept data from healthy volunteers in 2H26.
• The planned 4Q26 IND submission for Viridian's TSHR program.
• Viridian's expected 2026 communication of development plans for VRDN-006.